Healthcare AI and the Accountability-Value Gap

Why accelerating adoption is challenging how healthcare executives define, govern, and sustain enterprise value.

Executive Summary

Artificial intelligence is becoming an increasingly significant part of healthcare operations, clinical practice, and enterprise strategy. Adoption and experimentation continue to expand across the industry, accompanied by growing expectations for measurable financial, operational, and clinical outcomes. Yet the available evidence reveals an important distinction between deploying AI capabilities and consistently demonstrating the enterprise value those capabilities are expected to produce. Healthcare organizations are advancing AI initiatives while confronting unresolved questions about how value is defined, measured, governed, and sustained.

First Stage Advisors characterizes this emerging challenge as the accountability-value gap: the potential distance between an organization’s ability to deploy AI and its ability to demonstrate that those investments are producing meaningful, sustainable enterprise outcomes.

The gap does not necessarily indicate that AI investments are failing. Rather, it highlights the growing importance of executive decisions that extend beyond technology selection and implementation. Clinical, financial, operational, and technology leaders may hold different expectations for the same investment. Without a shared understanding of intended outcomes, enterprise priorities, decision authority, and accountability, individual initiatives may demonstrate promising results without establishing their collective contribution to organizational value.

Addressing this challenge requires three executive disciplines: Purpose, Priority, and Decision Authority. Leadership must establish what the organization intends to accomplish, which opportunities warrant commitment, and who is empowered and accountable to make consequential decisions. These disciplines must extend beyond initial implementation. As technologies, evidence, and organizational conditions evolve, executives must continually reassess whether investments remain aligned with enterprise objectives and whether anticipated benefits are being realized.

The central challenge for healthcare leadership is not simply accelerating AI adoption. It is ensuring that expanding AI capabilities are supported by the executive alignment, governance, and sustained accountability necessary to translate technological potential into measurable enterprise value.

Healthcare AI Is Advancing, but the Market Is Not Making a Simple Transition

Artificial intelligence is becoming an increasingly significant component of healthcare operations, clinical practice, and enterprise strategy. Health systems, health plans, and other healthcare organizations are exploring and deploying AI across administrative, financial, clinical, and operational functions. The evidence, however, does not support a simple narrative that healthcare is moving beyond experimentation into a new era of consistently demonstrated enterprise value. Instead, two developments are occurring simultaneously.

AI adoption and experimentation continue to expand. At the same time, expectations for measurable financial, operational, and clinical outcomes are increasing. Healthcare executives are being asked not only whether their organizations should adopt AI, but whether those investments are delivering meaningful value, how that value is measured, and who is accountable for achieving it.

This creates a challenge that extends beyond technology selection and implementation. For healthcare leaders, the emerging question is whether the organizational structures responsible for defining priorities, making decisions, measuring results, and sustaining accountability are keeping pace with the technologies being introduced.

First Stage Advisors characterizes this tension as the accountability-value gap: the potential distance between an organization’s ability to deploy AI capabilities and its ability to consistently define, demonstrate, and sustain the enterprise value those capabilities are expected to produce. The gap is not necessarily evidence that AI investments are failing. Rather, it identifies a set of executive responsibilities that become increasingly important as AI adoption accelerates.

Adoption Is Expanding Across the Healthcare Enterprise

Federal data confirms that AI is becoming more prevalent in hospital operations. According to the Assistant Secretary for Technology Policy/Office of the National Coordinator for Health Information Technology (ASTP/ONC), approximately 71% of U.S. hospitals reported using predictive AI integrated with their electronic health record systems in 2024, compared with 66% in 2023. The same federal research identified substantial increases in reported use for selected operational functions, including billing and scheduling.

These findings demonstrate that AI is no longer confined to isolated innovation programs. It is increasingly present in established healthcare workflows. However, adoption is not uniform. Smaller, rural, and critical access hospitals continue to face different levels of access, resources, and implementation capacity. The organizational implications of AI therefore vary considerably across the healthcare market.

Physician use is also expanding. The American Medical Association’s 2026 research reported that 81% of physicians surveyed were using AI professionally, although that measure includes general-purpose AI applications and should not be interpreted as enterprise-level deployment.

Commercial health system research likewise indicates growing interest in both implementing and evaluating AI solutions. A 2026 survey by Eliciting Insights reported that 75% of participating U.S. health systems had implemented or were planning AI initiatives, compared with 59% in the prior survey period. That measure combines implementation and planned activity, so it does not establish that three-quarters of participating systems had deployed AI in production.

Taken together, these findings support a clear conclusion: healthcare AI activity is expanding across multiple settings and functions. They do not establish that experimentation is declining, that organizations are consistently scaling successful pilots, or that deployment is producing measurable enterprise-wide value.

Those distinctions matter. An organization may have numerous AI initiatives underway without having established a common understanding of their relative importance, the outcomes they should produce, or the executive decisions required to sustain them. As AI becomes more accessible, the challenge of enterprise prioritization may grow rather than diminish.

Deployment and Demonstrated Value Are Different Measures of Progress

The expanding presence of AI creates understandable expectations for improved performance. Healthcare executives are evaluating potential benefits that include reduced administrative burden, improved workforce capacity, stronger revenue cycle performance, better clinical decision support, and more effective use of organizational resources. Yet the available evidence reveals an important distinction between implementing AI and consistently measuring its financial and operational contribution.

Deloitte’s 2026 research involving 64 U.S. healthcare finance executives found that only 18% of organizations scaling generative AI consistently measured its financial impact, compared with 31% among earlier adopters. These figures describe the measurement practices reported by a specific survey population. They should not be generalized to all U.S. healthcare organizations. Nevertheless, they raise a consequential executive question.

If an organization expands its use of AI faster than it develops the ability to measure outcomes, how will leadership determine which investments warrant continued support, modification, expansion, or termination?

The problem is not simply the availability of financial metrics. Healthcare AI investments may generate benefits across multiple dimensions, some of which are difficult to translate directly into financial returns. A clinical documentation application, for example, might reduce time spent completing notes, improve clinician experience, increase available capacity, or influence documentation quality. These outcomes are related, but they are not interchangeable. An improvement in clinician experience does not automatically establish a positive financial return. Time saved does not necessarily translate into increased productive capacity. Improved workflow performance does not, by itself, demonstrate enterprise-wide benefit.

Peer-reviewed randomized research on ambient AI documentation tools illustrates this complexity. A University of Wisconsin Health study reported improvements in work exhaustion and reductions in documentation time. Research involving physicians at UCLA found differing results across ambient documentation products, including a statistically significant reduction in note-writing time for one tool but not another. These studies provide evidence of potentially meaningful clinical workflow benefits. They do not establish that every ambient AI implementation will produce comparable results.

Independent assessment by the Peterson Health Technology Institute has similarly identified encouraging evidence for clinician experience while noting uncertainty surrounding net financial return. The implications extend beyond ambient documentation.

Organizations need to distinguish between anticipated benefits, observed operational improvements, measurable financial results, and sustained enterprise value. Each represents a different level of evidence. The appropriate measure of success should be determined by the purpose of the investment, not simply by the metrics most readily available after implementation.

Enterprise Value Depends on Whose Outcomes Are Being Measured

Healthcare organizations do not operate with a single, universally accepted definition of value.

• Clinical leaders may prioritize patient safety, care quality, clinician workload, and the patient experience.

• Financial executives may focus on operating margin, cost avoidance, revenue realization, capital requirements, and financial sustainability.

• Operational leaders may emphasize workforce capacity, throughput, productivity, and reliability.

• Technology executives must also account for integration, cybersecurity, vendor dependencies, data quality, support requirements, and long-term technical sustainability.

• For health plans, additional considerations include medical cost management, administrative efficiency, utilization review, member experience, and regulatory obligations.

These perspectives are legitimate. They can also create competing priorities.

An AI initiative that appears successful within one department may introduce costs, dependencies, or operational consequences elsewhere in the organization. For example, improved documentation and coding capabilities may create financial benefits for a provider while raising different concerns for payers. The broader debate over coding intensity and reimbursement illustrates how value can be interpreted differently across healthcare stakeholders.

Such differences should not be resolved by assuming that one stakeholder’s preferred metric represents enterprise value. Instead, leadership must establish how competing objectives will be evaluated, which tradeoffs are acceptable, and who has authority to make those decisions.

This is particularly important when an AI investment spans clinical, financial, operational, and technology functions. Without an agreed enterprise value framework, individual initiatives can appear successful while the organization remains uncertain about their collective contribution. A comprehensive assessment should consider not only the benefits produced but also the resources required to implement, operate, monitor, and sustain the capability.

The available U.S. research does not yet provide consistent, independently measured total-cost-of-ownership and net-return evidence across healthcare AI applications. That limitation reinforces the need for organizations to develop their own disciplined approach to evaluating value rather than relying exclusively on vendor projections, isolated performance indicators, or market-wide expectations.

AI Governance Is Becoming an Enterprise Leadership Responsibility

The expanding use of AI introduces governance considerations that extend beyond traditional technology oversight. AI capabilities may influence clinical recommendations, administrative decisions, financial outcomes, workforce processes, and interactions with patients and members. Consequently, governance must address more than whether a technology functions as intended. It must also establish the organizational conditions under which that technology should be used, monitored, modified, or discontinued.

Federal hospital research indicates that AI evaluation frequently involves multiple organizational participants. Approximately 74% of hospitals using predictive AI reported multiple entities with accountability for evaluation. Multiple participants are not inherently a governance weakness. Cross-functional participation may be essential when AI affects different parts of the enterprise. The more consequential issue is whether responsibilities and decision rights are sufficiently clear.

• Who determines whether a proposed AI application supports enterprise priorities?

• Who establishes acceptable performance and risk thresholds?

• Who resolves disagreements when clinical, financial, operational, and technical objectives conflict?

• Who has authority to pause or discontinue a capability when expected benefits fail to materialize or circumstances change?

• And who remains accountable after an AI solution moves from initial implementation into routine operations?

These are executive governance questions, even when their implementation requires specialized clinical, technical, legal, or compliance expertise.

External expectations are also evolving. The Joint Commission and the Coalition for Health AI have published voluntary guidance addressing responsible AI use in healthcare settings. Individual states are establishing requirements affecting selected AI applications, including payer utilization review. Federal policy continues to evolve as well, including changes to health information technology certification requirements and the allocation of responsibilities among technology developers, healthcare organizations, and other participants.

The resulting environment is not a single, stable regulatory framework. Requirements vary by application, jurisdiction, and organizational role. Healthcare executives therefore need governance structures that can adapt as technology capabilities, evidence, and external obligations change. A policy document or oversight committee may be necessary, but neither is sufficient by itself. Effective governance requires an operating model in which decisions are made at the appropriate level, relevant stakeholders participate, responsibilities are explicit, and results are reviewed over time.

The Executive Challenge: Purpose, Priority, and Decision Authority

The evidence points toward a leadership challenge that becomes more consequential as AI opportunities multiply. Healthcare organizations can evaluate promising applications, launch pilots, select vendors, and implement technology without first resolving fundamental questions about enterprise purpose and priorities.

The resulting activity may be substantial, but activity alone does not establish strategic progress. Three executive disciplines are particularly relevant.

Purpose: What enterprise outcome are we trying to achieve?

AI should be evaluated in relation to defined organizational needs. The purpose may involve improving access, strengthening financial performance, reducing administrative burden, supporting clinical quality, or addressing workforce constraints. What matters is that the intended outcome is sufficiently clear to guide investment decisions and subsequent evaluation. When purpose is ambiguous, organizations risk selecting solutions based on technological capability rather than organizational necessity. A compelling demonstration of what AI can do is not the same as an executive decision about what the organization needs it to accomplish.

Priority: Which opportunities warrant organizational commitment?

As AI becomes embedded in existing applications and new products enter the market, healthcare organizations face an expanding range of potential investments. Not every opportunity can or should receive equal attention. Executive prioritization requires consideration of strategic relevance, expected value, organizational readiness, risk, resource requirements, and competing initiatives. This includes understanding dependencies across functions and recognizing that a locally attractive investment may not represent the best use of enterprise capacity. Prioritization must also remain dynamic. An initiative that merits investment today may require reconsideration as evidence develops, operating conditions change, or more consequential opportunities emerge.

Decision Authority: Who is empowered and accountable to act?

Cross-functional involvement is essential, but participation does not automatically produce clear accountability. Organizations must establish who recommends, who evaluates, who decides, who implements, and who is responsible for monitoring outcomes. Decision authority becomes especially important when performance is uncertain, risks emerge, or competing executive priorities cannot all be satisfied. Without clarity, unresolved decisions can migrate upward, return repeatedly to executive leadership, or remain suspended between organizational functions. The objective is not to centralize every AI decision. It is to establish a decision structure that allows the organization to act coherently, with appropriate oversight and clear accountability.

Together, Purpose, Priority, and Decision Authority provide a foundation for connecting AI activity to enterprise objectives. They are not substitutes for technical evaluation, clinical validation, financial analysis, or regulatory compliance. They establish the executive context within which those activities can produce coordinated organizational value.

 

Sustaining Value Requires More Than Initial Alignment

Even well-defined initiatives encounter changing conditions. New evidence may challenge original assumptions. Financial pressures may alter priorities. Clinical or operational experience may reveal consequences that were not visible during evaluation. AI technologies themselves may change through model updates, new functionality, revised vendor offerings, or integration with other enterprise systems. These developments make sustained organizational alignment particularly important.

An executive team may agree on the initial purpose of an investment yet gradually develop different interpretations of success, acceptable risk, or the resources needed to continue. Governance arrangements that work during selection and implementation may become less effective as responsibility transitions into ongoing operations. Performance monitoring must therefore examine more than technical functionality. Leadership should periodically reassess whether the capability continues to serve its intended purpose, whether expected benefits are being realized, whether organizational dependencies have changed, and whether decision authority remains appropriate.

This is not a recommendation to create additional governance activity for its own sake. The objective is to preserve the organization’s ability to make timely, informed decisions as circumstances evolve. It is also important to distinguish a sound executive management principle from a demonstrated research outcome.

The available evidence does not establish that a particular executive alignment methodology produces superior AI returns across U.S. healthcare organizations. It does, however, identify unresolved questions concerning value definition, measurement, governance, and accountability that executive leadership must address. Those questions warrant deliberate attention regardless of the AI technology selected.

What Healthcare Executives Should Do Now

The immediate leadership priority is not necessarily to accelerate AI adoption or to slow it down. It is to ensure that the organization’s approach to AI remains connected to its strategic objectives, operational realities, and capacity to demonstrate value. That begins with an enterprise-level examination of existing and proposed initiatives.

Leadership should understand which AI capabilities are already operating, which remain experimental, which are being considered, and what each is expected to accomplish. More importantly, executives should be able to explain how those initiatives relate to organizational priorities.

A useful assessment would examine several questions:

• Are expected outcomes defined in terms that relevant executive stakeholders understand and accept?

• Are financial, clinical, operational, and workforce implications considered together rather than independently?

• Is there a clear basis for prioritizing investments and reallocating resources?

• Are decision rights and accountability explicit across the lifecycle of each initiative?

• Does leadership receive meaningful evidence about realized benefits, ongoing costs, risks, and changing conditions?

• Is there a process for revisiting assumptions and correcting course when results differ from expectations?

These questions do not require an organization to wait for perfect evidence before acting. They require leadership to recognize where evidence is incomplete and establish how decisions will be made under those conditions.

• For organizations early in AI adoption, this may mean strengthening the executive foundation before committing to a broader portfolio of initiatives.

• For organizations already operating multiple AI capabilities, it may mean reassessing the relationship between deployed technologies, enterprise priorities, and demonstrated outcomes.

• For organizations preparing to scale successful applications, it may mean confirming that the operating model, governance responsibilities, and measurement capabilities can support expansion.

The appropriate response depends on the organization’s circumstances. The common requirement is executive clarity.

The First Stage Advisors Perspective

Healthcare AI presents significant opportunities, but the availability of increasingly capable technology does not eliminate the organizational work required to achieve enterprise value. The research suggests that healthcare executives are navigating two realities simultaneously: expanding AI adoption and increasing expectations for measurable, accountable outcomes.

The challenge is not simply deciding which technologies deserve investment. It is establishing the executive alignment necessary to determine what the organization intends to accomplish, how competing priorities will be resolved, who has authority to act, and how value will be evaluated as conditions change.

This is the organizational dimension addressed by First Stage Advisors. Our Pulse Methodology™ is designed to help healthcare leadership teams establish Executive Alignment through a shared understanding of Purpose, Priority, and Decision Authority before consequential initiatives move forward. Through our Voice of the Stakeholder™ approach, we examine how executive participants understand organizational objectives, expected value, cross-functional dependencies, and the decisions required for success. That perspective informs a unified executive framework for defining measurable value, clarifying accountability, and identifying areas where apparent agreement may conceal different expectations. Our Pulse Advisory Retainers™ are designed to extend that attention beyond initial alignment, supporting periodic reassessment of priorities, decision effectiveness, emerging risks, and organizational alignment as initiatives progress.

These services are not substitutes for AI implementation expertise, technical governance, clinical oversight, or financial validation. They address the executive and organizational decisions that influence how those specialized capabilities are directed and coordinated.

As AI becomes a more pervasive part of healthcare operations, the ability to sustain enterprise alignment may become increasingly consequential. Organizations will continue to encounter new technologies, new evidence, and new expectations for performance. The enduring executive responsibility is to ensure that these developments remain connected to a coherent definition of organizational value.

The question is no longer simply what AI can accomplish. It is whether healthcare organizations have established the leadership clarity, decision authority, and ongoing accountability necessary to turn expanding AI capabilities into sustainable enterprise value.

---

Research Scope and Limitations

This Insight draws on U.S. healthcare research and industry findings available through November 2026. The referenced studies represent different populations, methodologies, and measures of AI adoption, performance, and value. Their findings should not be interpreted as a single measure of industry progress or as evidence that AI deployment consistently produces measurable enterprise returns. The accountability-value gap is an executive framework developed by First Stage Advisors to examine the organizational implications of these findings.